|
業務類別
|
Biotechnology |
|
業務概覽
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib,a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
| 公司地址
| 3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 465-6511 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.erasca.com |
| 員工數量
| 103 |
| Dr. Shannon R. Morris, M.D.,PhD |
Chief Medical Officer |
美元 486.50K |
29/04/2025 |
| Dr. David M. Chacko, M.D. |
Chief Financial Officer, Principal Accounting Officer and Chief Business Officer |
美元 492.10K |
29/04/2025 |
| Dr. Jonathan E. Lim,M.D. |
Chairman of the Board and Chief Executive Officer |
美元 644.60K |
29/04/2025 |
| Mr. Ebun S. Garner |
General Counsel and Corporate Secretary |
-- |
29/04/2025 |
|
|
| Dr. James A. Bristol, PhD |
Lead Independent Director |
29/04/2025 |
| Dr. Julie Hambleton, M.D. |
Independent Director |
29/04/2025 |
| Dr. Pratik S. Multani, M.D. |
Independent Director |
29/04/2025 |
| Dr. Michael D. Varney, PhD |
Director and Chair of Research and Development |
29/04/2025 |
| Dr. Jonathan E. Lim,M.D. |
Chairman of the Board and Chief Executive Officer |
29/04/2025 |
| Ms. Jean I. Liu, J.D. |
Independent Director |
29/04/2025 |
| Mr. Alexander W. Casdin |
Independent Director |
29/04/2025 |
| Dr. Valerie Harding Start, PhD |
Independent Director |
29/04/2025 |
|
|
|
|
